# Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic Canc

Source: https://onco.cc/trials/nct06571461/  
OnCo record `nct06571461` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of liposomal irinotecan, cAPOX (capecitabine, oxaliplatin), tegafur, gimeracil and oteracil (S-1), gemcitabine and other drugs in pancreatic cancer, run by CSPC Ouyi Pharmaceutical Co., Ltd., not yet recruiting.

## Summary

Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic Cancer is a phase 3, randomised interventional study registered as NCT06571461 by CSPC Ouyi Pharmaceutical Co., Ltd., with a registry enrolment figure of 408 participants, started 2024-09 and due to reach its primary completion in 2028-01. Interventions recorded: Liposomal Irinotecan; Oxaliplatin; S-1; Gemcitabine; Capecitabine. Conditions listed: Pancreatic Cancer. Primary outcome: Disease-free survival (DFS). Pancreatic eligibility wording from the registry: "Histologically confirmed resected ductal pancreatic adenocarcinoma (including adenosquamous carcinoma)". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT06571461
- Phase: 3
- Setting: A Randomized, Open-label, Multi-center Phase III Clinical Study of Liposomal Irinotecan Combined With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine for Postoperative Adjuvant Treatment of Pancreatic Cancer
- Sponsor: CSPC Ouyi Pharmaceutical Co., Ltd.
- Enrolled: 408

## Sources

- ClinicalTrials.gov NCT06571461: https://clinicaltrials.gov/study/NCT06571461

## Connected records

- cancers: [Resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/resectable-pdac/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/), [CAPOX (capecitabine, oxaliplatin)](https://onco.cc/drugs/capox/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Liposomal irinotecan](https://onco.cc/drugs/liposomal-irinotecan/), [Tegafur, gimeracil and oteracil (S-1)](https://onco.cc/drugs/tegafur-gimeracil-oteracil/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06571461.json